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Abstract
Background: A new capsule endoscopy (CE) system featuring two advanced optics for 344°-viewing and a
prolonged operative time has been recently developed for Crohn’s disease (CD) patients. Hence, we evaluated, for
the first time, the performance of this novel CE and the add-on value of the 344°-viewing in a multi-center real-life
setting.
Methods: Consecutive patients with suspected or established CD received the PillCam™ Crohn’s System as
supplementary diagnostic work-up focused on the small-bowel between June 2017 and June 2018. Technical and
clinical data, including the panenteric CE diagnostic yield, the Lewis score and the impact of small-bowel findings
on clinical management during a 6-months follow-up (new diagnosis, staging or treatment upgrade) were
collected, thereby evaluating the added value of the 344° panoramic-view (lesions detected by camera A and B)
over the standard 172°-view (lesions detected by one camera only).
Results: Among 41 patients (aged 43 ± 20 years), 73% underwent CE for suspected CD and 27% for established CD.
The rate of complete enteroscopy was 90%. No technical failure or retention occurred. Compared to the standard
172° view, the panoramic 344°-view revealed a greater number of patients with a relevant lesion (56.1% vs. 39.0%;
P = 0.023), resulting in higher Lewis score (222,8 vs. 185.7; P = 0.031), and improved clinical management (48.8% vs.
31.7%, P = 0.023).
Conclusions: The panoramic 344°-view increases small-bowel CE accuracy, thereby improving the clinical
management of CD patients with mild small-bowel active disease. This system should be regarded as a new
standard for both small-bowel diagnosis and monitoring in inflammatory bowel diseases.
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Background
Capsule endoscopy (CE) is the most sensitive diagnostic
tool for the diagnosis of small-bowel mucosal lesions in
Crohn’s disease (CD) patients [1–4]. Furthermore, CE
has emerged as a key tool for disease staging (i.e. loca-
tion, extent, severity) and monitoring, facilitating a re-
fined clinical classification and tight control
management [5–8].
In recent years, a colonic capsule with an extended
battery life and cameras on both sides has been adapted
for use in inflammatory bowel diseases (IBD) as a mini-
invasive approach for panenteric endoscopy in post-
operative follow-up, children and special situations [9–
11].
In 2017 a new capsule system designed for CD pa-
tients was released (PillCam™ Crohn’s System, PCS;
Medtronic, Dublin, Ireland) [11, 12]. The PCS capsule is
equipped with two advanced optics enabling a 344°-wide
view between both capsule heads and with a prolonged
operative time (≥12 h) to provide the panoramic
visualization of the entire GI tract within a single endo-
scopic procedure. PCS includes a renewed software
(Rapid 9) for capsule localization and dedicated applica-
tions to classify disease severity and extent according to
structured descriptors or the Lewis score (LS) [11, 12].
The aim of the present multi-center study was: firstly to
evaluate for the first time the performances of the novel
PillCam™ Crohn’s system (PCS) in a multi-center clinical
practice setting; secondly, to determine whether the
344°-panoramic view provided by its novel dual-ended
camera can improve the small-bowel detection rates and
the assessment of the Lewis score, thereby resulting in a
different clinical management of CD patients.
Methods
Study population and CE procedure
All consecutive patients undergoing CE for suspected or
established CD were enrolled at two Italian IBD centers
between June 2017 and June 2018. According to the
current guidelines and international consensus, patients
with “suspected CD” were defined by the presence of
suspicious symptoms of active small-bowel CD (i.e. ab-
dominal pain, diarrhoea and weight loss) following in-
consistent findings at ileocolonoscopy and
esophagogastroduodenoscopy plus either extra-intestinal
manifestations, inflammatory markers (i.e. C-reactive
protein and faecal calprotectin), or abnormal imaging
studies [1, 2, 13]. Patients with known CD underwent
CE for either disease staging or monitoring following
upper and/or lower endoscopy as a part of routine diag-
nostic work-up [1–3]. Cross-sectional imaging or pa-
tency capsule were performed in established CD and in
selected patients with suspected CD [1–3].
All CE procedures were conducted using the novel
novel PCS. This system includes a dual-camera capsule
device with prolonged battery life potentially allowing
for pan-enteric wireless capsule endoscopy and an opti-
mized platform specifically designed to assess IBD mu-
cosal disease severity and extent over time. Technical
details of the PCS have been recently described in detail
elsewhere [14].
All the patients provided their informed consent,
followed a clear liquid diet for 24 h plus 12 h fasting and
received 2 L of polyethylene glycol solution 2–8 h before
capsule ingestion according to the local center protocols
for small-bowel cleansing.
Technical and clinical outcomes
For each procedure, technical (e.g. transit and operative
times, technical failures, small-bowel completion rate),
clinical (e.g. endoscopic findings, Lewis Score, capsule
impact on clinical management) and safety (e.g. capsule
retention and aspiration) data were collected by struc-
tured data entry. All the endoscopic findings detected
along the digestive tract were systematically classified ac-
cording to location (i.e. upper GI, three small-bowel ter-
tiles, colon) and endoscopic relevance, after reaching a
perfect agreement between two expert capsule readers.
Consistent with the literature, the presence of diffuse
edema, ulcers, and strictures were defined as “relevant
endoscopic findings for the diagnosis of active CD” [15].
The Lewis Score (LS) was calculated to assess the
small-bowel CD diagnosis and activity. Briefly, the LS
uses the CE structured terminology (edema, ulcer, and
strictures) to grade disease activity into three levels: i) no
or clinically insignificant (LS < 135); ii) mild (135 ≤ LS
≤790); iii) moderate to severe (LS > 790) [14, 15]. Peptic
disorders, vascular and inflammatory lesions were
assessed following established classifications [16–18].
During a 6-months follow-up, the “impact of CE on
clinical management” was defined as positive when
strongly supporting a definite diagnosis for patients with
suspected CD, as well as when leading to refined disease
staging or treatment strategy upgrade for established CD
patients. Since all patient had previously received colon-
oscopy, only small bowel findings were considered when
assessing the impact of CE on clinical management. A
“definite diagnosis of CD” was defined in patients with
relevant capsule endoscopy findings for the diagnosis of
active CD plus coherent device-assisted enteroscopy
with histopathology or cross-sectional imaging during
follow-up [3]. A “treatment strategy upgrade” was con-
sidered for patients receiving treatment (add on or
switch to) steroids, immunomodulators or biologics dur-
ing follow-up [5, 6, 8].
Four expert capsule readers with a substantial clinical
and endoscopic background in the IBD field were
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involved (GET, FC, MS, CC). Firstly, the capsule records
were evaluated by two independents readers to define
the exact location and endoscopic relevance of each
endoscopic finding. Then, the capsule readers reviewed
separately the two capsule camera recordings to ascer-
tain whether each relevant endoscopic finding was
clearly identified by either capsule camera A or B or
both. In order to prevent findings duplication, the endo-
scopic findings presenting with an identical location and
similar features (morphology, size) were accounted as a
unique lesion. A perfect agreement between the 2 inde-
pendents reviewers was required before data entry.
Data analysis
The rate of patients with at least one relevant endo-
scopic finding throughout the GI tract (i.e., panenteric
diagnostic yield), the Lewis Score and the impact of
small-bowel findings on clinical management were sep-
arately calculated for the capsule camera recording A +
B and capsule camera recording A to measure the added
value of the 344°-wide panoramic-view (capsule camera
A and B) over the standard CE 172°-wide view (one cap-
sule camera only).
The descriptive statistics were presented as mean ± SD
for continuous variables and percentages for categorical
variables. Categorical variables were analyzed by the
McNemar test, while continuous variables by the Wil-
coxon test.
This study was carried out in accordance with the
Declaration of Helsinki adopted in 1964 incorporating
all later amendments.
Results
Overall, 41 patients (16 men; age: 43 ± 20 years) were
consecutively enrolled; 73% (30/41) of them underwent
CE for suspected CD, while 27% (11/41) for established
CD with a mean time of 12 years elapsed from diagnosis
(Table 1).
All the patients with established CD had a negative pa-
tency test, while no suspected CD ones received a
patency capsule. No technical failure, nor capsule reten-
tion or aspiration occurred.
The mean gastric transit time, small-bowel transit time
and operative time were respectively 34 ± 31 min, 264 ±
221 min and 11.8 ± 3.3 h.
Small-bowel visibility was graded as good to optimal,
while colon visibility as poor to fair in all the
procedures.
The rate of complete enteroscopy was 90%; incomplete
enteroscopy occurred due to ulcerated narrowings (2
cases in suspected, 1 in established CD) and diffuse in-
flammation (1 case in established CD). As far as the
Lewis score calculation is concerned, incomplete enter-
oscopies were excluded from the Lewis score analysis.
Overall, 122 lesions were found; of them, 55 (45.1%)
were classified as relevant and distributed in duodenum
(10.9%), jejunum (32.7%), ileum (43.6%) or colon (12.7%)
(Fig. 1). The patients with one or more panenteric rele-
vant lesions were 23/41 (56.1%): 46.7% of those who per-
formed CE for suspected CD and 81.8% for established
CD. Notably, when diffuse edema was accounted as a
relevant lesion, at least one additional and harder cap-
sule finding has been also clearly identified, including
ulcer and/or stricture.
Within the suspected-CD group with relevant lesions
at CE, all detected lesions were confined to the small-
bowel and one patient had an isolated duodenal ulcer,
which had been missed by previous upper endoscopy
and even diagnosed as a peptic disorder.
Overall, the mean Lewis score was 222,8 ± 347.1. Pa-
tients with suspected CD had a mean Lewis score of
107 ± 162, while those with established CD had a mean
Lewis score of 580 ± 516. Overall, 51.4% of patients had
Lewis score ≥ 135 (39.3% in suspected CD, 77.7% in
established CD patients).
During a 6-month follow up, the small bowel finding
resulting from CE investigation had an impact on the
clinical management in 48.8% of patients, leading to the
final diagnostic definition for 43.3% of patients with sus-
pected CD (12 new diagnosis of CD and one peptic dis-
ease) and to disease staging upgrade (2 patients),
Table 1 Study population - demographic and clinical data
Study population (n = 41) Suspected CD (n = 30) Established CD (n = 11)
Gender (Women / Men) 25 / 16 21 / 9 4 / 7
Age (median ± SD, years) 43 ± 20 39 ± 22 37 ± 11
Years from diagnosis (median ± SD, years) / / 10 ± 11
Baseline Montreal classification L1 / L2 / L3 / / 7 / 3 / 1
Baseline Montreal classification B1 / B2 + B3 / / 11 / 0
Completion ratea 90.2% 93.3% 81.8%
Positive capsule / Lewis score (median ± SD)ba 23 / 222,8 ± 347.1 14 / 107 ± 162 9 / 580 ± 516
aIncomplete enteroscopy occurred due to ulcerated narrowings (2 in suspected and 1 in established CD) and diffuse inflammation (1 case in established CD)
bOne CE was positive for duodenal peptic disease in the suspected CD group; this case was not included in the Lewis score calculation
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treatment escalation (4 patients) or both (one patient)
for 63.6% of those with established CD (Table 2).
As compared to the standard 172° view, the panoramic
344°-view detected 17.1% more patients with at least one
relevant lesion (56.1% vs. 39.0%; P = 0.023; Video 1),
resulting in a 16.6% increase of the mean LS (222.8 vs.
185.7; P = 0.031), and a 17.1% increase in the number of
patients with improved clinical management (48.8% vs.
31.7%, P = 0.023) (Table 2).
Discussion
This observational multi-center study represents the first
series of consecutive patients undergoing CE with the
novel PCS in a clinical practice setting. This system fea-
tures two independent optics placed on both capsule
edges providing a 344°-wide panoramic-view to improve
endoscopic detection and characterization throughout
the entire GI tract [11, 19]. A recent pilot study has sug-
gested that PCS would possibly result in higher diagnos-
tic yields than ileo-colonoscopy in patients with known
Fig. 1 Top left, proximal duodenitis with aphthous ulcers. Top right, an isolated ulcer, 8 mm in size, identified only by one in the terminal ileum.
Lower right, a deep ulcer, 10 mm in size, in the right colon. Lower left, jejunal narrowing with a large, superficial ulcer
Table 2 Impact of standard and panoramic viewing in suspected and established CD patients
One Camera (172°-view) Two cameras (344°-view)
Lewis Score (overall population) 185.7 222.8
Lewis Score in suspected CD 97 107
Lewis Score established CD 442 580
New diagnosis of CDa 10/30 13/30
Montreal class upgrade 1/11 3/11
Treatment strategy upgrade 3/11 5/11
a New diagnosis of CD was defined for relevant CE findings strongly supporting a definite diagnosis following a 6-months follow-up
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active CD following a capsule colon cleansing protocol
[12]. PCS showed to be safe and to enable the direct
evaluation of the entire gut based on the preliminary
data from a proof-of-concept feasibility study conducted
on CD and ulcerative colitis patients [14].
Our study confirms the high technical and diagnostic
performances of the PCS in patients with suspected or
established CD. No safety nor technical issues were ob-
served, the small-bowel completion rate was > 90% and
the capsule operating time was 11.8 ± 3.3 h, thereby
largely fitting with the panenteric assessment [9–11]. In
fact, PCS identified several lesions in the duodenum and
colon, confirming the potential of the 344°-wide pano-
ramic view as a first triage tool for panenteric endoscopy
in IBD.
However, the present observational study was carried
out in a real life setting where CE examinations are per-
formed as a supplementary diagnostic work-up on the
small-bowel mucosa, thereby avoiding the large bowel
cleansing. As a result, PCS revealed relevant small-bowel
findings supporting the new diagnosis of CD (LS ≥ 135)
in one-third of the patients with suspected CD. In estab-
lished CD patients, the recognition of active small-bowel
disease resulted in refined disease staging and targeted
treatment escalation, thereby strengthening the emer-
ging role of CE in two-thirds of cases [5–7]. These re-
sults are consistent with those reported in two
longitudinal studies conducted with standard-view CE
devices showing an impact on clinical management in
34–52% of established CD patients [6, 8].
No previous study has ever assessed whether the pecu-
liar 344°-wide panoramic-view of the novel PCS can
offer any advantage in clinical practice over the standard
172°-view even in the small-bowel. Consistently, we have
performed a post hoc revision of all PCS video records
to ascertain whether each relevant endoscopic finding
was clearly identified by either capsule camera A or B.
Then, we compared the diagnostic outcomes and the
contribution to the clinical outcomes resulting from
standard 172°-view (one camera only) and 344°-wide
panoramic view (camera A and B). Surprisingly, the
panenteric CE diagnostic yield and the Lewis score re-
sulted remarkably enhanced with the 344°-wide pano-
ramic view. More interestingly, 344°-wide panoramic
view resulted in a Δ + 17% examinations with a real im-
pact on patients’ clinical management. This initial evi-
dence suggests the PCS as a more accurate and effective
device for small bowel CE in IBD patients. Further stud-
ies should now confirm this figure in larger cohorts of
patients stratified according to the severity of the small-
bowel involvement. In fact, the predominance of mild to
moderate active disease observed in our population
(mean LS = 222,8 ± 347.1) could have highlighted the
add-on value of the panoramic 344°-viewing CE, which
is supposed to be less relevant in severe CD
enteropathies.
Potential limitations of the present study must be ad-
dressed. Firstly, given the observational design, our cap-
sule readers were not blinded either to previous
investigations or to the yield of the “single-view” camera.
Secondly, despite the exact number and location of find-
ings appears substantial using the renewed Rapid 9 soft-
ware for capsule localization, anterograde and retrograde
movements may result in an unbalanced overestimation
of detected lesions between the 172° and 344° capsule
view. Thirdly, according to the current European guide-
lines on IBD [1–3], CE was performed as a supplemen-
tary diagnostic work-up following a previous ileo-
colonoscopy. Therefore, no colon cleansing protocol was
performed before CE to avoid the double administration
of substantial purgative agents, thereby reducing the
diagnostic potential of PCS into the colon. In addition,
two little shortcomings related to the use of the PCS
should be also mentioned. The dual camera-viewing im-
plies additional images to be downloaded and assessed.
This might increase the reading time of about 5–10min
even if the operator assesses the two cameras simultan-
eously in dual mode. The present version of the PCS
provides a lower image quality as compared to the Pill-
Cam SB3 [20].
Conclusions
This proof of concept pilot multi-center study carried
out in routine clinical practice confirms that the novel
PillCam™ Crohn’s system is safe and provides high tech-
nical and endoscopic performances for CD assessment
[12, 14]. Our results also suggest that the panoramic
344°-view clearly improves small-bowel capsule visual-
isation, thus potentially improving both diagnostic ac-
curacy and clinical management for patients undergoing
small bowel CE for suspected or established CD.
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